摘要
目的研究替格瑞洛治疗急性冠脉综合征(ACS)的临床疗效及对患者炎症因子、心功能的影响。方法选取2019年10月-2022年10月弋阳县人民医院收治的71例ACS患者,经随机数字表法分为对照组(35例)与观察组(36例)。对照组行常规药物治疗,观察组则在其基础上联合替格瑞洛治疗,比较两组临床疗效、炎性因子[C反应蛋白(CRP)、白介素(IL-6、IL-18)]、心功能[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)]、主要不良心血管事件(MACE)及不良反应情况。结果观察组治疗总有效率高于对照组(P<0.05)。两组治疗后CRP、IL-6、IL-18水平均低于治疗前,且观察组CRP、IL-6、IL-18水平低于对照组(P<0.05)。两组治疗后LVEF大于治疗前,LVEDD小于治疗前,且观察组LVEF大于对照组,LVEDD小于对照组(P<0.05)。观察组MACE发生率小于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论替格瑞洛可提升ACS患者的临床疗效,下调炎症因子水平,改善心功能,可降低MACE风险,且不增加药物不良反应。
Objective To study the clinical efficacy of ticagrelor in the treatment of acute coronary syndrome(ACS)and its effect on inflammatory factors and cardiac function.Methods A total of 71 patients with ACS admitted to Yiyang County People's Hospital from October 2019 to October 2022 were selected and divided into control group(35 patients)and observation group(36 patients)by random number table method.The control group was treated with conventional drugs,while the observation group was treated with ticagrelor on the basis of the control group.The clinical efficacy,inflammatory factors[C-reactive protein(CRP),interleukin(IL-6,IL-18)],cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD)],major adverse cardiovascular events(MACE)and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of CRP,IL-6 and IL-18 in the two groups were lower than those before treatment,and the levels of CRP,IL-6 and IL-18 in the observation group were lower than those in the control group(P<0.05).After treatment,LVEF in the two groups was greater than that before treatment,LVEDD was less than that before treatment,and LVEF in the observation group was greater than that in the control group,LVEDD was less than that in the control group(P<0.05).The incidence of MACE in the observation group was lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Ticagrelor can improve the clinical efficacy of ACS patients,down-regulate the level of inflammatory factors,improve cardiac function,reduce the risk of MACE,and do not increase adverse drug reactions.
作者
俞伟峰
龚丽珍
王飞云
YU Wei-feng;GONG Li-zhen;WANG Fei-yun(Department of Emergency,Yiyang County People's Hospital,Yiyang 334400,Jiangxi,China;Department of Cardiology,Yiyang County People's Hospital,Yiyang 334400,Jiangxi,China)
出处
《医学信息》
2024年第13期114-117,共4页
Journal of Medical Information
关键词
急性冠脉综合征
替格瑞洛
C反应蛋白
心功能
抗血小板治疗
Acute coronary syndrome
Ticagrelor
C-reactive protein
Cardiac function
Antiplatelet therapy
